- Home
- Areas of Research
Advancing therapeutics against liver cancer
Liver cancer is the fifth most common cancer and the third leading cause of cancer-related deaths globally1. Surgery, including orthotopic liver transplantation (OLT), remains the most effective treatment for patients with hepatocellular carcinoma (HCC)1, 2.
Read More
Advancing therapeutics against anemia
Anemia is a condition resulting from low levels of red blood cells or hemoglobin, the body's main oxygen-carrying components. It is a common side effect of chemotherapy, which is used to treat a variety of cancers.
Read More
Advancing therapeutics against hepatitis C
Diseases caused by chronic viral infections such as hepatitis C virus (HCV) are a growing public health problem. Up to 170 million people worldwide have chronic HCV infection1, including 3.2 million people in the US2. Chronic HCV infection is a major risk factor for developing liver cancer and is a leading cause for liver transplants1.
Read More
- Platform Technologies
Platform technologies that enhance therapeutics
In this age of molecular medicine, to be considered truly innovative drugs must be targeted to act specifically
at the organ, tissue, cellular or molecular level where disease processes are at play. Yet most drugs today are given systemically in a non-targeted approach. Another issue with molecular medicine is the challenge of a short drug half-life.
Read More
Making proteins work better by extending their half-life
Our half-life extension platform technology uses oxidized HES (hydroxyethyl starch) to improve physical and pharmacological characteristics of protein drugs. Our novel conjugation approach links a protein drug to HES thereby extending the drug's half-life, increasing its bioactivity, and allowing for the slow release of drug in the circulation.
Read More
- Pipeline
tbi 302
Targeted treatment against liver cancer TBI 302 is a hemoglobin-conjugated floxuridine compound undergoing clinical studies for the treatment of liver cancer. Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related deaths globally.
Read More
tbi 304H
Targeted treatment against anemia TBI 304H is a humanized monoclonal antibody designed to target the CD163 receptor pathway on hematopoietic progenitor cells as a potential treatment of anemia. This receptor is involved in the development of red blood cells from hematopoietic progenitor cells.
Read More
tbi 301
Targeted treatment against chronic hepatitis C infection
TBI 301 is a hemoglobin-conjugated ribavirin (RBV) compound designed to target RBV to the liver. Ribavirin is an antiviral drug that constitutes the current standard of care1,2, in combination with PEGylated interferon-a (PEG-IFNa), for the treatment of chronic hepatitis C virus (HCV) infection.
Read More
- partnering
|